Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2022 Feb:52:244-249.
doi: 10.1016/j.coviro.2021.12.010. Epub 2021 Dec 29.

Hepatitis C virus and intracellular antiviral response

Jiyoung Lee  1 , Jing-Hsiung J Ou  2
Affiliations
Review

Hepatitis C virus and intracellular antiviral response

Jiyoung Lee et al. Curr Opin Virol. 2022 Feb.

Abstract

To establish successful infection in cells, it is essential for hepatitis C virus (HCV) to overcome intracellular antiviral responses. The host cell mechanism that fights against the virus culminates in the production of interferons (IFNs), IFN-stimulated genes (ISGs) and pro-inflammatory cytokines as well as the induction of autophagy and apoptosis. HCV has developed multiple means to disrupt the host signaling pathways that lead to these antiviral responses. HCV impedes signaling pathways initiated by pattern-recognition receptors (PRRs), usurps and uses the antiviral autophagic response to enhance its replication, alters mitochondrial dynamics and metabolism to prevent cell death and attenuate IFN response, and dysregulates inflammasomal response to cause IFN resistance and immune tolerance. These effects of HCV allow HCV to successful replicate and persist in its host cells.

PubMed Disclaimer

Conflict of interest statement

Declaration of Interest:

None.

Figures

Figure 1.
Figure 1.
Illustration of interaction between HCV and various cellular pathways including IFN signaling, TLR signaling, apoptosis, autophagy, mitophagy and inflammasomes in cells. Please see text for details.
See this image and copyright information in PMC

References

    1. Gotte M, Feld JJ: Direct-acting antiviral agents for hepatitis C: structural and mechanistic insights. Nat Rev Gastroenterol Hepatol 2016, 13:338–351. - PubMed
    1. Majumdar A, Kitson MT, Roberts SK: Systematic review: current concepts and challenges for the direct-acting antiviral era in hepatitis C cirrhosis. Aliment Pharmacol Ther 2016. - PubMed
    1. Major ME, Mihalik K, Fernandez J, Seidman J, Kleiner D, Kolykhalov AA, Rice CM, Feinstone SM: Long-term follow-up of chimpanzees inoculated with the first infectious clone for hepatitis C virus. J Virol 1999, 73:3317–3325. - PMC - PubMed
    1. Sung PS, Shin EC: Interferon Response in Hepatitis C Virus-Infected Hepatocytes: Issues to Consider in the Era of Direct-Acting Antivirals. Int J Mol Sci 2020, 21. - PMC - PubMed

    2. This article provides an updated review of recent studies on type I and type III IFNs signaling in HCV-infected hepatocytes and the impact of direct-acting antivirals on IFN responses to HCV infection.

    1. Stetson DB, Medzhitov R: Type I interferons in host defense. Immunity 2006, 25:373–381. - PubMed

Publication types